---
title: "Esperion Therapeutics Closes Merger; Sets $100M CVR Plan, Amends 2030 Notes, Replaces Credit Facility"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292494712.md"
description: "Esperion Therapeutics completed its merger, implementing a $100M Contingent Value Rights (CVR) plan for milestone payments. The company amended its 2030 convertible notes to reflect post-merger conversion terms in cash and CVRs. Additionally, Esperion secured new debt financing from BioPharma Credit to fund the transaction and terminated its existing 2024 credit facility."
datetime: "2026-07-13T13:13:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292494712.md)
  - [en](https://longbridge.com/en/news/292494712.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292494712.md)
generator: "portal-rs"
---

# Esperion Therapeutics Closes Merger; Sets $100M CVR Plan, Amends 2030 Notes, Replaces Credit Facility

Esperion Therapeutics finalized a series of agreements tied to the completion of its merger, including a Contingent Value Rights (CVR) Agreement offering up to $100 million in potential milestone payments. The company also executed a Second Supplemental Indenture for its 5.75% convertible notes due 2030, setting post-merger conversion economics in cash and CVRs, including enhanced make-whole terms. In parallel, Esperion entered into a new loan agreement led by BioPharma Credit to fund the cash consideration and related needs, and repaid and terminated its 2024 credit facility. Together, these steps align capital structure and investor incentives with the company’s post-merger outlook.

**Agreement 1: Esperion Therapeutics Implements CVR Agreement Tied to Merger, Up to $100 Million Milestones**

-   **Agreement type**: Contingent Value Rights Agreement
-   **Counterparty**: Essence Parent; Computershare (Rights Agent)
-   **Signed / Effective**: Jul 13 2026 / Jul 13 2026
-   **Duration / Termination**: Milestone periods per agreement
-   **Reason**: Implement merger consideration with contingent payouts

**Agreement 2: Esperion Therapeutics Amends 2030 Convertible Notes Terms After Merger; Cash and CVR Conversion Set**

-   **Agreement type**: Second Supplemental Indenture for 5.75% Convertible Senior Subordinated Notes due 2030
-   **Counterparty**: Essence Parent; U.S. Bank Trust Company (Trustee)
-   **Signed / Effective**: Jul 13 2026 / Jul 13 2026
-   **Duration / Termination**: Until 2030 maturity
-   **Reason**: Align convertible notes with merger terms

**Agreement 3: Esperion Therapeutics Secures New Debt Financing With BioPharma Credit to Support Merger**

-   **Agreement type**: Loan agreement for merger financing
-   **Counterparty**: BioPharma Credit; BPCR; BioPharma Credit Investments V (Master)
-   **Signed / Effective**: Jul 13 2026 / Jul 13 2026
-   **Reason**: Finance acquisition and refinance prior debt

**Agreement 4: Esperion Therapeutics Retires 2024 Credit Agreement After Merger; Facility Repaid and Terminated**

-   **Agreement terminated**: Credit Agreement
-   **Counterparty**: GLAS USA; GLAS Americas; lenders and issuing banks
-   **Original agreement date**: Dec 13 2024
-   **Termination date**: Jul 13 2026
-   **Termination type**: Early
-   **Reason**: Refinance with new loan and consummation of merger

Original SEC Filing: Esperion Therapeutics, Inc. \[ ESPR \] - 8-K - Jul. 13, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [ESPR.US](https://longbridge.com/en/quote/ESPR.US.md)
- [CPU.AU](https://longbridge.com/en/quote/CPU.AU.md)
- [USB.US](https://longbridge.com/en/quote/USB.US.md)

## Related News & Research

- [Esperion stockholders approve merger agreement at special meeting](https://longbridge.com/en/news/292068833.md)
- [Esperion acquired in cash-and-CVR merger transaction](https://longbridge.com/en/news/292521304.md)
- [Werewolf Therapeutics agrees to merge with Ambros Therapeutics in all-stock deal](https://longbridge.com/en/news/296615000.md)
- [HMOBI board signs off on Q2 2026 financial statements, audit review shows no qualifications](https://longbridge.com/en/news/296656112.md)
- [ES Group to present January–June interim report in webcast and conference call](https://longbridge.com/en/news/296326732.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**